Skip to main
ACET

ACET Stock Forecast & Price Target

ACET Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adicet Bio is a promising company with an innovative pipeline of off-the-shelf gamma delta T cell therapies for autoimmune diseases and cancer. While the company may face clinical risks related to safety, their products have shown potential for mitigating adverse events compared to other cell therapies. Furthermore, the company has a strong financial outlook, with a recent product sales increase and potential for continued growth based on the success of their most advanced product candidate, prulacabtagene leucel.

Bears say

Adicet Bio is a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Despite showing promising efficacy in LN/SLE patients, there are several potential risks and uncertainties surrounding Adicet's main product candidate, prulacabtagene leucel (prula-cel). These include potential regulatory hurdles, such as FDA approval for Vδ1 gamma-delta T-cell therapies, and currency risks associated with future royalty payments. Additionally, Adicet's competition in the highly competitive autoimmune landscape could pose challenges for the company's success. As a result, the negative outlook for Adicet Bio's stock is largely based on these potential risks and uncertainties.

ACET has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adicet Bio, Inc. (ACET) Forecast

Analysts have given ACET a Strong Buy based on their latest research and market trends.

According to 4 analysts, ACET has a Strong Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adicet Bio, Inc. (ACET)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.